L’actualité de Novigenix
Suivez toute l’actualité de Novigenix
Novigenix AI Spin-Out to Accelerate AI-Powered Immune Intelligence
Epalinges, Switzerland, March 5, 2026 – Novigenix SA, a leader in immunotranscriptomic diagnostics, today announced the formal spin-out and launch of Novigenix AI, a new precision medicine company dedicated to transforming therapy development through AI-powered immune intelligence. A Strategic Separation to Unlock Two High-Growth Markets The new AI spin-out separates Novigenix's colorectal cancer (CRC) screening business from its rapidly
Novigenix AI awarded EUR 1.8M in the groundbreaking BRECISE IHI Consortium to industrialize AI-powered liquid biopsy for prediction of immunotherapy response
Lausanne, Switzerland, March 31, 2025 – Novigenix AI, a leader in AI-driven precision liquid biopsy solutions, has been awarded EUR 1.8M through the new BRECISE IHI grant funded by the European Union (EU) research initiative focusing on revolutionizing cancer diagnostics, treatment, and monitoring through advanced multi-omics and artificial intelligence. The BRECISE consortium was launched last week in Madrid at
New study reveals novel multi-omics approach with unprecedented treatment response prediction in metastatic urothelial cancer
Lausanne, Switzerland, March 11, 2025 - Novigenix AI, a leader in AI-driven healthcare solutions, has published a groundbreaking study showcasing the predictive power of its LITOSeek™ platform for immunotherapy response in metastatic urothelial cancer. The study titled, “Multimodal Integration of Blood RNA and ctDNA Reflects Response to Immunotherapy in Metastatic Urothelial Cancer” [link], has been published in JCI Insight.
Breakthrough study reveals blood transcriptomic alternations for early detection of colorectal cancer
Lausanne, Switzerland, November 25, 2024 – Novigenix AI, a leader in AI-driven healthcare solutions, has published a new study marking a significant milestone in advancing early colorectal cancer (CRC) detection through innovative immune system profiling. The groundbreaking research, “Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression,” [link] has been published in the Journal for Immunotherapy of Cancer. Dr. Pedro Romero, Chief
Understanding Tumor Immunology: How AI-powered blood RNA analysis could unlock immunotherapy prognoses
By Pedro Romero, Chief Medical & Scientific Officer of Novigenix AI - Identifying markers in body fluids via liquid biopsy holds great promise for detecting diseases (such as cancer) at early stages, following disease progression and population heterogeneity, and, importantly, predicting a response to therapy with minimal patient inconvenience. Liquid biopsy relies on easy access to a multitude of
Prostate cancer breakthrough: Novigenix AI-led project receives €1.75M grant to improve patient outcomes using liquid biopsy technology
Lausanne, Switzerland, September 24, 2024 – Groundbreaking funding promises to revolutionize care for patients with advanced prostate cancer by addressing treatment resistance through innovative liquid biopsy technology. Novigenix AI, a leader in AI-driven healthcare solutions, has today announced the approval of a Eurostars grant for the MYeloid SIGNATUREs (MY-SIGNATURE) project. This prestigious grant, totaling a consortium budget of €1.75